company background image
BBIO

BridgeBio Pharma NasdaqGS:BBIO Stock Report

Last Price

US$11.08

Market Cap

US$1.6b

7D

-0.09%

1Y

-77.6%

Updated

16 Aug, 2022

Data

Company Financials +
BBIO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

BBIO Stock Overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.

BridgeBio Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BridgeBio Pharma
Historical stock prices
Current Share PriceUS$11.08
52 Week HighUS$53.57
52 Week LowUS$4.98
Beta0.71
1 Month Change23.25%
3 Month Change56.28%
1 Year Change-77.63%
3 Year Change-61.34%
5 Year Changen/a
Change since IPO-59.78%

Recent News & Updates

Aug 10
Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%

Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%

Shareholders in BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) may be thrilled to learn that the analysts have just delivered a...

Aug 04

BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M

BridgeBio Pharma press release (NASDAQ:BBIO): Q2 GAAP EPS of -$0.07 beats by $0.65. Revenue of $73.75M (+36.5% Y/Y) beats by $48.75M. Cash, cash equivalents and marketable securities, excluding restricted cash, at Q2 end increased by $55.1M when compared to the balance as of March 31, 2022 of $633.5M.

Shareholder Returns

BBIOUS BiotechsUS Market
7D-0.09%1.8%4.5%
1Y-77.6%-22.2%-8.9%

Return vs Industry: BBIO underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: BBIO underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is BBIO's price volatile compared to industry and market?
BBIO volatility
BBIO Average Weekly Movement17.3%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: BBIO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: BBIO's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015577Neil Kumarhttps://www.bridgebio.com

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

BridgeBio Pharma Fundamentals Summary

How do BridgeBio Pharma's earnings and revenue compare to its market cap?
BBIO fundamental statistics
Market CapUS$1.64b
Earnings (TTM)-US$509.36m
Revenue (TTM)US$90.67m

18.1x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BBIO income statement (TTM)
RevenueUS$90.67m
Cost of RevenueUS$5.05m
Gross ProfitUS$85.62m
Other ExpensesUS$594.98m
Earnings-US$509.36m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.44
Gross Margin94.43%
Net Profit Margin-561.78%
Debt/Equity Ratio-166.8%

How did BBIO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BBIO?

Other financial metrics that can be useful for relative valuation.

BBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue29.2x
Enterprise Value/EBITDA-5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BBIO's PS Ratio compare to its peers?

BBIO PS Ratio vs Peers
The above table shows the PS ratio for BBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.1x
XNCR Xencor
6.4x17.0%US$1.9b
VCYT Veracyte
6.4x13.8%US$1.7b
CDNA CareDx
3.8x12.4%US$1.2b
LGND Ligand Pharmaceuticals
7.6x5.8%US$1.8b
BBIO BridgeBio Pharma
18.1x30.2%US$1.6b

Price-To-Sales vs Peers: BBIO is expensive based on its Price-To-Sales Ratio (18.1x) compared to the peer average (6.1x).


Price to Earnings Ratio vs Industry

How does BBIO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: BBIO is expensive based on its Price-To-Sales Ratio (18.1x) compared to the US Biotechs industry average (16.9x)


Price to Sales Ratio vs Fair Ratio

What is BBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.1x
Fair PS Ratio30.4x

Price-To-Sales vs Fair Ratio: BBIO is good value based on its Price-To-Sales Ratio (18.1x) compared to the estimated Fair Price-To-Sales Ratio (30.4x).


Share Price vs Fair Value

What is the Fair Price of BBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BBIO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

  • Take a look at our analysis of BBIO's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Future Growth

How is BridgeBio Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BBIO's revenue (30.2% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: BBIO's revenue (30.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BBIO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has BridgeBio Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-37.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BBIO is currently unprofitable.

Growing Profit Margin: BBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BBIO is unprofitable, and losses have increased over the past 5 years at a rate of 37.7% per year.

Accelerating Growth: Unable to compare BBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: BBIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is BridgeBio Pharma's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BBIO has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BBIO has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 35% each year.


Discover healthy companies

Dividend

What is BridgeBio Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BBIO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BBIO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Neil Kumar (43 yo)

7.33yrs

Tenure

US$25,626,959

Compensation

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder and serves as Chief Executive Officer and Director BridgeBio Pharma, Inc. since April 2015 and serves as President...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD25.63M) is above average for companies of similar size in the US market ($USD5.42M).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BBIO's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: BBIO's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BridgeBio Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BridgeBio Pharma, Inc.
  • Ticker: BBIO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.643b
  • Shares outstanding: 148.25m
  • Website: https://www.bridgebio.com

Number of Employees


Location

  • BridgeBio Pharma, Inc.
  • 421 Kipling Street
  • Palo Alto
  • California
  • 94301
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.